Metagenomi
A US gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot.
In January 2022, Metagenomi announced the completion of an up-sized and oversubscribed $175 million Series B financing.
This brings the total amount of funding for the company to $300 million. Proceeds from the financing will be used to advance Metagenomi’s lead in vivo and ex vivo gene editing therapeutic programs through pre-clinical development and into the clinic. This will include expansion of its manufacturing, automation and AI infrastructure, and further development of the company’s differentiated toolbox of next-generation gene editing systems.
Latest Metagenomi News & Features
6 February 2024
25 January 2024
15 March 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze